K2 Principal Fund, L.P. Black Diamond Therapeutics, Inc. Transaction History

K2 Principal Fund, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$1.35 - $3.14 $198,282 - $461,190	-146,876 Reduced 92.85%	11,316 $21,000
Q4 2022 Feb 10, 2023	SELL	$1.27 - $2.51 $1.11 Million - $2.19 Million	-873,319 Reduced 84.66%	158,192 $284,000
Q3 2022 Nov 14, 2022	BUY	$1.68 - $4.01 $880,083 - $2.1 Million	523,859 Added 103.19%	1,031,511 $1.74 Million
Q2 2022 Aug 12, 2022	BUY	$1.5 - $3.63 $761,478 - $1.84 Million	507,652 New	507,652 $1.25 Million

118

48.8M

1.84M

1.93M

Ticker BDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,339,500
Market Cap $99.2M
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...

Get notified when there are updates to the investment portfolio of K2 Principal Fund, L.P., based on Form 13F filings with the SEC.

Stay updated on K2 Principal Fund, L.P. with notifications on news.